COPD – Discover Pharma

Welcome to Discover Pharma! Today is : June 11, 2026

COPD

Drug Delivery & Formulation,Medical devices,Pharmaceuticals and therapeutics
Nebu~Flow secures £2M Scottish Enterprise grant for nebuliser technology
Glasgow medical technology company Nebu~Flow has secured a £2 million [...]

June 8, 2026
Clinical & Regulatory,Opinion & Events,Therapeutic Areas
World Bronchiectasis Conference returns to Hannover after decade of progress
The World Bronchiectasis Conference (WBC) will return to Hannover, Germany, [...]

June 8, 2026
Biotech & Pharma Business,Clinical & Regulatory
NICE recommends Nucala for uncontrolled COPD with eosinophilic phenotype on NHS
NICE has issued draft final guidance recommending Nucala as an [...]

June 6, 2026
Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas
Tozorakimab meets primary endpoint in two Phase 3 COPD trials, showing reduction in exacerbations
Tozorakimab has met its primary endpoint in two replicate Phase [...]

May 5, 2026
Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Genomics and sequencing,Therapeutic Areas
Flagship Pioneering signs new agreements with ProFound Therapeutics and Quotient Therapeutics with GSK collaboration
Flagship Pioneering has announced that ProFound Therapeutics and Quotient Therapeutics [...]

May 5, 2026
Digital & Data,Drug Discovery & Development,Medical devices,Opinion & Events,Pharmaceuticals and therapeutics,Therapeutic Areas
electronRx to launch app for remote respiratory disease management
electronRx will launch its pDx app at the HLTH 2025 [...]

May 5, 2026

This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK